Achieving Superior Treatment Durability and Outcomes in Neovascular AMD and DME


Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

0:00 Introduction

0:52 Need for durable treatments in nAMD and DME

4:20 Mechanism of faricimab

7:10 Highlights from clinical trials for faricimab

10:28 Post hoc analyses of faricimab clinical trials

16:19 Factors affecting retreatment decision

19:20 Durability data for faricimab

23:22 Experience with faricimab

29:00 Choosing between faricimab and high-dose aflibercept

32:47 Final remarks

Related Videos
A panel of 3 experts on dry eye
A panel of 3 experts on ocular diseases and conditions
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
© 2024 MJH Life Sciences

All rights reserved.